文献速递糖尿病

PAM单倍剂量不足不加速饮食及人IAPP诱导的小鼠糖尿病发生

PAM haploinsufficiency does not accelerate the development of diet- and human IAPP-induced diabetes in mice.
PubMed 文献 · Diabetologia · 2020-01-27

研究探讨肽基甘氨酸α-酰胺化单加氧酶(PAM)在β细胞肽酰胺化、功能和糖尿病发生中的作用。Pam+/-与Pam+/+小鼠分别喂食低脂或高脂饮食,并在β细胞表达人胰岛淀粉样多肽(hIAPP)模型中评估。结果显示PAM单倍剂量不足不影响糖耐量、胰岛素敏感性或胰岛淀粉样物形成。

要点

  • PAM在人类胰岛α、β、δ细胞中高表达,高脂饮食及内质网或细胞因子应激可降低小鼠胰岛Pam表达。
  • Pam+/-小鼠PAM表达和酶活性约为Pam+/+的50%,但糖耐量和体成分相当。
  • 高脂饮食24周后,Pam+/-与Pam+/+小鼠均出现胰岛素抵抗和糖耐量受损,但两组间无差异。

核心结论

  • 小鼠PAM单倍剂量不足不加速饮食诱导的肥胖或hIAPP转基因诱导的糖尿病发生。

研究设计与样本

  • 研究分析小鼠胰岛在诱导内质网或细胞因子应激后PAM转录和蛋白水平,并检查人胰岛PAM表达模式。
  • 为研究PAM单倍剂量不足是否加速糖尿病发生,Pam+/-与Pam+/+小鼠喂食低脂饮食(LFD)或高脂饮食(HFD)并评估血糖稳态。
  • 在β细胞表达hIAPP的Pam+/-与Pam+/+小鼠中,研究PAM单倍剂量不足是否加速hIAPP诱导的糖尿病和胰岛淀粉样物形成。

主要发现

  • 免疫染色显示PAM在人胰腺胰岛α、β和δ细胞中高表达。
  • 给予HFD后小鼠胰岛Pam mRNA和PAM蛋白表达降低,分离胰岛经毒胡萝卜素诱导内质网应激或经IL-1β、IFN-γ和TFN-α诱导细胞因子应激后PAM表达也降低。
  • 尽管Pam+/-小鼠PAM表达和酶活性仅为Pam+/+小鼠的50%,两种模型糖耐量和体成分相当。
  • HFD 24周后,Pam+/-与Pam+/+小鼠均出现胰岛素抵抗和糖耐量受损,但PAM单倍剂量不足小鼠在糖耐量、胰岛素敏感性或血浆胰岛素水平方面无差异。
  • 在β细胞表达hIAPP的Pam+/-与Pam+/+小鼠中,胰岛淀粉样物形成和β细胞功能也相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Peptide hormones are first synthesised as larger, inactive precursors that are converted to their active forms by endopeptidase cleavage and post-translational modifications, such as amidation. Recent, large-scale genome-wide studies have suggested that two coding variants of the amidating enzyme, peptidylglycine α-amidating monooxygenase (PAM), are associated with impaired insulin secretion and increased type 2 diabetes risk. We aimed to elucidate the role of PAM in modulating beta cell peptide amidation, beta cell function and the development of diabetes. METHODS: PAM transcript and protein levels were analysed in mouse islets following induction of endoplasmic reticulum (ER) or cytokine stress, and PAM expression patterns were examined in human islets. To study whether haploinsufficiency of PAM accelerates the development of diabetes, Pam+/- and Pam+/+ mice were fed a low-fat diet (LFD) or high-fat diet (HFD) and glucose homeostasis was assessed. Since aggregates of the PAM substrate human islet amyloid polypeptide (hIAPP) lead to islet inflammation and beta cell failure, we also investigated whether PAM haploinsufficiency accelerated hIAPP-induced diabetes and islet amyloid formation in Pam+/- and Pam+/+ mice with beta cell expression of hIAPP. RESULTS: Immunostaining revealed high expression of PAM in alpha, beta and delta cells in human pancreatic islets. Pam mRNA and PAM protein expression were reduced in mouse islets following administration of an HFD, and in isolated islets following induction of ER stress with thapsigargin, or cytokine stress with IL-1β, IFN-γ and TFN-α. Despite Pam+/- only having 50% PAM expression and enzyme activity as compared with Pam+/+ mice, glucose tolerance and body mass composition were comparable in the two models. After 24 weeks of HFD, both Pam+/- and Pam+/+ mice had insulin resistance and impaired glucose tolerance, but no differences in glucose tolerance, insulin sensitivity or plasma insulin levels were observed in PAM haploinsufficient mice. Islet amyloid formation and beta cell function were also similar in Pam+/- and Pam+/+ mice with beta cell expression of hIAPP. CONCLUSIONS/INTERPRETATION: Haploinsufficiency of PAM in mice does not accelerate the development of diet-induced obesity or hIAPP transgene-induced diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Chen YC, Mains RE, Eipper BA, et al. PAM haploinsufficiency does not accelerate the development of diet- and human IAPP-induced diabetes in mice. Diabetologia. 2020. PMID: 31984442. doi:10.1007/s00125-019-05060-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。